Alternative investigations for irritable bowel syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 73-77

  Philpott, Hamish ^a,b   Nandurkar, Sanjay ^a,b   Lubel, John ^a,b   Gibson, Peter R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b Department of Gastroenterology and Hepatology Eastern Health ^*  (Australia)

Author keywords

Clinical intestinal disorders; Colonic motility and disorders; Intestinal disorders

Indexed keywords

FOOD ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; SHORT CHAIN FATTY ACID;

ARTICLE; AUSTRALIA; CONTROLLED STUDY; DIAGNOSTIC TEST; FECES ANALYSIS; HUMAN; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MEDICAL ETHICS; PRIORITY JOURNAL; STANDARD; VALIDATION STUDY;

EID: 84871648480     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07291.x     Document Type: Article

References (45)

1. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment. Pharmacol. Ther. 2003; 17: 841-851.
2. Haddow JE, Palomaki GE. A model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, eds. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford: Oxford University Press, 2003; 217-233.
3. Greenhalgh T. How to read a paper. Papers that report diagnostic or screening tests. BMJ 1997; 315: 540-543.
4. Stapel SO, Asero R, Ballmer-Weber BK etal. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008; 63: 793-796.
5. Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand. J. Gastroenterol. 2005; 40: 800-807.
6. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 1459-1464.
7. Miller SB. IgG Food Allergy Testing by ELISA/EIA. What Do They Really Tell Us? 2008. Cited May 2011. Available from URL: http://www.tldp.com/issue/174/IgG%20Food%20Allergy.html
8. Corthesy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J. Immunol. 2007; 178: 27-32.
9. Ohman L, Lindmark AC, Isaksson S etal. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol. Motil. 2009; 21: 644-650.
10. Cremon C, Gargano L, Morselli-Labate AM etal. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am. J. Gastroenterol. 2009; 104: 392-400.
11. Neville V, Gleeson M, Folland JP. Salivary IgA as a risk factor for upper respiratory infections in elite professional athletes. Med. Sci. Sports Exerc. 2008; 40: 1228-1236.
12. Takatsuji K, Sugimoto Y, Ishizaki S, Ozaki Y, Matsuyama E, Yamaguchi Y. The effects of examination stress on salivary cortisol, immunoglobulin A, and chromogranin A in nursing students. Biomed. Res. 2008; 29: 221-224.
13. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006; 55: 1512-1520.
14. Spiller RC, Jenkins D, Thornley JP etal. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
15. Dunlop SP, Hebden J, Campbell E etal. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am. J. Gastroenterol. 2006; 101: 1288-1294.
16. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol. Motil. 2007; 19: 545-552.
17. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther. 2004; 20: 1317-1322.
18. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2008; 28: 994-1002.
19. Francavilla R, Miniello V, Magista AM etal. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010; 126: e1445-1452.
20. Zareie M, Johnson-Henry K, Jury J etal. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55: 1553-1560.
21. Laker MF, Menzies IS. Increase in human intestinal permeability following ingestion of hypertonic solutions. J. Physiol. 1977; 265: 881-894.
22. Bjarnason I, Williams P, So A etal. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 2: 1171-1174.
23. Arrieta MC, Madsen K, Doyle J, Meddings J. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2009; 58: 41-48.
24. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N. Engl. J. Med. 1989; 320: 23-28.
25. Sengupta S, Tang CL, Wong CS, Tjandra JJ, Gibson PR. Colonic epithelial atrophy induced by a fibre-free diet in rats is reversed by minimal amounts of luminal butyrate, but only in the short term. ANZ J. Surg. 2002; 72: 871-876.
26. Govers MJ, Gannon NJ, Dunshea FR, Gibson PR, Muir JG. Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs. Gut 1999; 45: 840-847.
27. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010; 22: 512-519, e114-15.
28. Mortensen PB, Andersen JR, Arffmann S, Krag E. Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran. Scand. J. Gastroenterol. 1987; 22: 185-192.
29. Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J. Pediatr. Gastroenterol. Nutr. 1996; 23: 280-286.
30. McIntyre A, Vincent RM, Perkins AC, Spiller RC. Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors. Gut 1997; 40: 223-227.
31. Mcintyre A, Gibson PR, Young GP. Butyrate production from dietary fiber and protection against large-bowel cancer in a rat model. Gut 1993; 34: 386-391.
32. Sengupta S, Tang CL, Wong CSM, Tjandra JJ, Gibson PR. Colonic epithelial atrophy induced by a fibre-free diet in rats is reversed by minimal amounts of luminal butyrate, but only in the short term. ANZ J. Surg. 2002; 72: 871-876.
33. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 2001; 81: 1031-1064.
34. Othman M, Aguero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr. Opin. Gastroenterol. 2008; 24: 11-16.
35. Pimentel M, Lembo A, Chey WD etal. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 2011; 364: 22-32.
36. Pimentel M, Chang C. Inflammation and microflora. Gastroenterol. Clin. North Am. 2011; 40: 69-85.
37. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009; 9: 15.
38. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008; 14: 2650-2661.
39. Pimentel M, Morales W, Chua K etal. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig. Dis. Sci. 2011; 56: 2067-2072.
40. Ford AC, Talley NJ, Quigley EM, Moayyedi P. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum 2009; 52: 1805; author reply 6.
41. Arumugam M, Raes J, Pelletier E etal. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
42. Langhorst J, Junge A, Rueffer A etal. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2009; 104: 404-410.
43. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 2008; 103: 162-169.
44. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2002; 97: 1755-1762.
45. Spiller RC. Potential biomarkers. Gastroenterol. Clin. North Am. 2011; 40: 121-139.